Johannes-Peter Stasch is a Chief Scientist in Cardiovascular Research at Bayer Pharma in Wuppertal, and Honorary Professor of Drug Discovery at the University Halle-Wittenberg. He studied chemistry and pharmaceutical sciences, earned a doctorate from the University of Würzburg, and received his Habilitation for Pharmacology at the University Halle-Wittenberg. He has more than 30 years’ experience in the areas of biochemistry, pharmacology and drug discovery. |
 |
He has played the leading role in the discovery and development of the sGC stimulators and the sGC activators. Very recently, the most advanced drug, Riociguat has been approved under the trade name Adempas® by FDA for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension. His research has led to more than 200 patent applications, several development compounds, and finally Riociguat. Stasch is a scientific organizer of the International cGMP Conferences, has published more than 150 original publications, and 25 book chapters. He has been selected as a member of the National Academia of Science, Leopoldina.
|
(View the Abstract) 
